FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111740219> ?p ?o ?g. }

• W2111740219 endingPage "1443" @default.
• W2111740219 startingPage "1434" @default.
• W2111740219 abstract "Erythropoietin was recently shown to exert important cytoprotective and anti-apoptotic effects in injury models of the brain, heart and kidney. We examined whether erythropoietin also attenuates renal injury in a rat model of unilateral ureteral obstruction via anti-apoptotic and anti-inflammatory actions.We divided Sprague-Dawley rats (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea) into 4 groups, including 1-vehicle treated with sham operation, 2-vehicle treated with unilateral ureteral obstruction for 3 days, 3-erythropoietin treatment with sham operation and 4-erythropoietin treatment for unilateral ureteral obstruction for 3 days. The erythropoietin treatment dose was 3,000 IU/kg per day intraperitoneally, administered daily. We compared competitive reverse transcriptase-polymerase chain reaction data on transforming growth factor-beta, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, osteopontin, Fas and Bcl-2. Furthermore, we examined Western blots for caspase-3 and light microscopy findings with hematoxylin and eosin staining. We applied immunohistochemistry for transforming growth factor-beta, ED-1 and caspase-3, and TUNEL in each group.Transforming growth factor-beta, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, osteopontin and Fas mRNA levels in the erythropoietin treated, unilateral ureteral obstruction group were significantly lower than in the obstruction only group. The Bcl-2 mRNA level in the erythropoietin treated obstruction group was significantly higher than in the obstruction only group. Caspase-3 activity in the erythropoietin treated obstruction group was significantly lower than in the obstruction only group. On light microscopy interstitially infiltrated inflammatory cells were significantly decreased in the erythropoietin treated obstruction group compared to the obstruction only group. On immunohistochemistry the erythropoietin treated obstruction group showed significantly fewer reactions for transforming growth factor-beta, ED-1 and caspase-3 compared to the obstruction only group. Erythropoietin treatment in rats with unilateral ureteral obstruction significantly decreased the number of TUNEL positive cells.Erythropoietin exerts renoprotective effects in an experimental unilateral ureteral obstruction rat model via anti-apoptotic and anti-inflammatory actions." @default.
• W2111740219 created "2016-06-24" @default.
• W2111740219 creator A5004165798 @default.
• W2111740219 creator A5016304487 @default.
• W2111740219 creator A5019034500 @default.
• W2111740219 creator A5040859854 @default.
• W2111740219 creator A5058183473 @default.
• W2111740219 creator A5072255737 @default.
• W2111740219 creator A5073362619 @default.
• W2111740219 creator A5081668121 @default.
• W2111740219 date "2009-03-01" @default.
• W2111740219 modified "2023-10-02" @default.
• W2111740219 title "Erythropoietin Attenuates Renal Injury in an Experimental Model of Rat Unilateral Ureteral Obstruction via Anti-Inflammatory and Anti-Apoptotic Effects" @default.
• W2111740219 cites W1886472157 @default.
• W2111740219 cites W1980538933 @default.
• W2111740219 cites W2001767183 @default.
• W2111740219 cites W2004612291 @default.
• W2111740219 cites W2007425843 @default.
• W2111740219 cites W2028628328 @default.
• W2111740219 cites W2028638529 @default.
• W2111740219 cites W2035076162 @default.
• W2111740219 cites W2039714220 @default.
• W2111740219 cites W2043486948 @default.
• W2111740219 cites W2050057700 @default.
• W2111740219 cites W2056657456 @default.
• W2111740219 cites W2108089603 @default.
• W2111740219 cites W2121188367 @default.
• W2111740219 cites W2137002490 @default.
• W2111740219 cites W2137769557 @default.
• W2111740219 cites W2141425585 @default.
• W2111740219 cites W2152769492 @default.
• W2111740219 cites W2170023789 @default.
• W2111740219 doi "https://doi.org/10.1016/j.juro.2008.10.105" @default.
• W2111740219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19157461" @default.
• W2111740219 hasPublicationYear "2009" @default.
• W2111740219 type Work @default.
• W2111740219 sameAs 2111740219 @default.
• W2111740219 citedByCount "27" @default.
• W2111740219 countsByYear W21117402192012 @default.
• W2111740219 countsByYear W21117402192013 @default.
• W2111740219 countsByYear W21117402192014 @default.
• W2111740219 countsByYear W21117402192015 @default.
• W2111740219 countsByYear W21117402192016 @default.
• W2111740219 countsByYear W21117402192018 @default.
• W2111740219 countsByYear W21117402192020 @default.
• W2111740219 countsByYear W21117402192021 @default.
• W2111740219 countsByYear W21117402192023 @default.
• W2111740219 crossrefType "journal-article" @default.
• W2111740219 hasAuthorship W2111740219A5004165798 @default.
• W2111740219 hasAuthorship W2111740219A5016304487 @default.
• W2111740219 hasAuthorship W2111740219A5019034500 @default.
• W2111740219 hasAuthorship W2111740219A5040859854 @default.
• W2111740219 hasAuthorship W2111740219A5058183473 @default.
• W2111740219 hasAuthorship W2111740219A5072255737 @default.
• W2111740219 hasAuthorship W2111740219A5073362619 @default.
• W2111740219 hasAuthorship W2111740219A5081668121 @default.
• W2111740219 hasConcept C125473707 @default.
• W2111740219 hasConcept C126322002 @default.
• W2111740219 hasConcept C126894567 @default.
• W2111740219 hasConcept C134018914 @default.
• W2111740219 hasConcept C17991360 @default.
• W2111740219 hasConcept C190283241 @default.
• W2111740219 hasConcept C196795494 @default.
• W2111740219 hasConcept C204232928 @default.
• W2111740219 hasConcept C2778534260 @default.
• W2111740219 hasConcept C2781184567 @default.
• W2111740219 hasConcept C55493867 @default.
• W2111740219 hasConcept C71924100 @default.
• W2111740219 hasConcept C86803240 @default.
• W2111740219 hasConceptScore W2111740219C125473707 @default.
• W2111740219 hasConceptScore W2111740219C126322002 @default.
• W2111740219 hasConceptScore W2111740219C126894567 @default.
• W2111740219 hasConceptScore W2111740219C134018914 @default.
• W2111740219 hasConceptScore W2111740219C17991360 @default.
• W2111740219 hasConceptScore W2111740219C190283241 @default.
• W2111740219 hasConceptScore W2111740219C196795494 @default.
• W2111740219 hasConceptScore W2111740219C204232928 @default.
• W2111740219 hasConceptScore W2111740219C2778534260 @default.
• W2111740219 hasConceptScore W2111740219C2781184567 @default.
• W2111740219 hasConceptScore W2111740219C55493867 @default.
• W2111740219 hasConceptScore W2111740219C71924100 @default.
• W2111740219 hasConceptScore W2111740219C86803240 @default.
• W2111740219 hasIssue "3" @default.
• W2111740219 hasLocation W21117402191 @default.
• W2111740219 hasLocation W21117402192 @default.
• W2111740219 hasOpenAccess W2111740219 @default.
• W2111740219 hasPrimaryLocation W21117402191 @default.
• W2111740219 hasRelatedWork W1977918131 @default.
• W2111740219 hasRelatedWork W1990717759 @default.
• W2111740219 hasRelatedWork W2034366718 @default.
• W2111740219 hasRelatedWork W2098830437 @default.
• W2111740219 hasRelatedWork W2137584496 @default.
• W2111740219 hasRelatedWork W2167902350 @default.
• W2111740219 hasRelatedWork W2252641125 @default.
• W2111740219 hasRelatedWork W2354056392 @default.
• W2111740219 hasRelatedWork W2380423849 @default.
• W2111740219 hasRelatedWork W2394192597 @default.
• W2111740219 hasVolume "181" @default.

• next